adhesion glycoprotein that is up-regulated in the proximal tubule epithelial cells and modulates the regeneration and repair of a post-ischemic kidney injury (10, 11) . Urinary KIM-1 may distinguish acute tubular necrosis from other forms of acute renal injury or chronic renal insufficiency (12, 13) .
Urinary KIM-1 levels have been suggested as a valid biomarker of tubular injury in both acute and chronic heart failure, where renal dysfunction is common (14) . Urinary KIM-1 levels are increased in heart failure patients, and often parallel with clinical severity; therefore, they may predict cardiorenal syndrome, and may be associated with long-term outcomes in chronic heart failure (15) (16) (17) (18) . However, prospective measurement of plasma KIM-1 levels in ADHF, as well as evaluating their response to medical therapy and their impact on clinical outcomes, has not been well-established. Because urinary KIM-1 and plasma KIM-1 levels correlate, we hypothesize that plasma KIM-1 will show similar associations (19) . Patients were excluded if there was clinical evidence for acute coronary syndrome or baseline cardiac troponin >5Â the upper reference limit, as measured by the local clinical laboratory. The design and primary results of ASCEND-HF have been reported previously (20, 21) .Ofthe 7,411pa-tients randomly assigned, 904 were enrolled in the biomarker substudy. These subjects had serial venous blood sampling at baseline, at 48 to 72 h after therapy initiation, and at a 30-day follow-up visit (6, 22) . Blood samples were collected in ethylenediaminetetraacetic acid-plasma, immedi-ately centrifuged and stored at -80 F for subsequent analysis at a core laboratory. for recurrent heart failure within 30 days of ran· domization. Dyspnea response was analyzed as a dichotomous variable identifying those in whom dyspnea had moderately or markedly improved 6 to 24 h after being assigned randomly. Death and worsening heart failure were assessed together as a composite secondary endpoint and all events were adjudicated through 180 days.
ST A Tl STI CAL ANALYSE s. Baseline characteristics and renal outcomes were presented as median (interquartile range [IQRJ) for continuous variables and as percentage for categorical variables. The Jonckheere-Terpstra and Cochran-Armitage trend tests were used to assess the significance of a trend across increasing tertiles of KIM·l for continuous and categorical vari· ables, respectively. Double-sided p values 0.05 were considered significant. Circulating KIM·l levels were compared between patients randomly assigned to placebo or nesiritide via the Wilcoxon rank-sum test. Nonparametric linear correlates of other renal biomarkers to KIM·l levels were presented as Spearman correlation coefficients (p). The association between KIM·l and intermediate outcomes was performed via logistic regression analyses for improvement in dyspnea at 6 and 24 h, and death or worsening
heart failure in the hospital. After observing no trends with time for the Schoenfeld residuals, the association ofKIM·l and long-term outcomes was performed via Cox proportional hazards models for the endpoints of 30-day mortality, 30-day mortality or worsening heart failure, and 180-day mortality. For multivariable analyses, we adjusted for covariates that have been identified for the overall ASCEND-HF study population, as described previously (6, 22) . The Kaplan-Meier method was used to compare 180-day mor· tality across groups. Differences across tertiles of KIM·l levels and across strata of median KIM·l and median cystatin C were determined by the logrank test. All statistical analyses were performed using SAS software, version 9.3 (SAS Institute, Cary, North Carolina). KIM-1 may be an early marker of cardiorenal syndrome (15), because it is highly expressed on the surface of injured tubule epithelial cells and transforms epithelial cells into phagocytic cells, which clear apoptotic and necrotic cells after acute tubular injury (11) . As a result, urinary KIM-1 is a highly specific marker for acute tubular injury and is commonly increased in patients with heart failure (10, 17) .
However, less is known about plasma levels of KIM-1.
There are several reasons supporting its detection in the plasma after acute tubular injury: KIM-1 may be released directly into the interstitium through loss of tubular permeability and back-leak of contents into the circulation via breakdown of the microvascular architecture of the endothelial cells and basement membrane (32) (33) (34) . Plasma KIM-1 levels correlate well with urinary KIM-1 levels and are associated with renal dysfunction (19) .Consistent with urinary KIM-1 levels, our finding that plasma KIM-1 levels were only modestly correlated with other renal indices ( Table 3) may imply other renal physiologic processes that are not reflected by more traditional metrics of renal function (16) .Further-more, we observed that increased plasma KIM-1 at baseline is associated with decreased diuresis and a greater incidence of renal dysfunction ( Table 4) , and is higher in subjects who developed worsening renal function by 72 h (Figure 1) , indicating that circul-ating KIM-1 levels do reflect some degree of renal insufficiency.
Although baseline urinary KIM-1 has been shown to yield incremental prognostic information to esti-mated glomerular filtration in chronic heart failure, data from patients with ADHF have not shown the same association between elevated urinary KIM-1 and poor prognosis (16) (17) (18) . Our current findings with circulating levels also demonstrated no incremental benefit of KIM-1 levels when measured in plasma beyond more traditional markers of renal function in ADHF. There may be several potential explana-tions for this finding.
First, altered central or renal hemodynamics as a result of increased venous con-gestion and/or decreased cardiac output may affect glomerular filtration more than tubular function in the kidneys. Second, although KIM·l is a sensitive marker for tubular injury resulting from nephrotoxic medications, the degree of tubular injury may not be as severe during ADHF, as indicated by previous studies on urinary neutrophil gelatinaseassociated lipocalin, which is another marker of renal tubular damage (35,36). There was a trend of higher KIM -1 in the nesiritide versus placebo groups, but there was a limited impact on clinical outcomes between treatment groups, and there was no interaction with 30-day KIM·l levels and nesiritide treatment. Therefore, using a surro-gate marker of tubular injury without assessing "hard" adverse outcomes remains a challenge.
STUDY LIMITATIONS. The results of this study must be interpreted in light of various limitations inherent to its design. First, the absence of overlap between creatinine, cystatin C, and blood urea nitrogen values in conjunction with the KIM·l draws
(48 to 72 hand 30 days of blood sampled and analyzed in the core laboratory versus clinically collected creatinine and blood urea nitrogen levels at baseline, 24 h, and at the end of treatment) and the absence of available urine output data past 24 h, limit our ability to assess cardiorenal outcomes during the remainder of hos-pitalization. Second, there was a paucity of data to assess the additional contribution of other heart failure pharmacotherapies on the incidence of renal insufficiency or clinical outcomes. Finally, although nesiritide use was associated with higher follow-up KIM-1 levels, caution should be used in interpreting these results, because this study was not appropriately powered to demonstrate such a difference. Regardless, with carefully adjudicated outcomes, our analysis suggests that there is little role for measuring plasma KIM-1 and predicting adverse clinical outcomes in ADHF, but does provide insight into renal tubular damage in heart failure and its prognostic implications.
CONCLUSIONS
In our study cohort, circulating KIM-1 at baseline and during hospitalization was not associated with adverse clinical outcomes in ADHF after adjusting for standard indices of kidney function. Nesiritide use may be associated with a greater rise in circulating KIM-1 levels, although its use did not correlate with adverse clinical outcomes.
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